PROF vs EDAP

For growth investors, Profound Medical Corp.

(PROF) is the stronger pick with 61. 1% revenue growth year-over-year, versus 10. 3% for Edap Tms S. a. (EDAP). Profound Medical Corp. (PROF) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Profound Medical Corp. (PROF) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Edap Tms S.

a. (EDAP) delivered a total return of -37. 8%, compared to -64. 5% for Profound Medical Corp. (PROF). Over 10 years, the gap is even starker: EDAP returned +18. 9% versus PROF's -26. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edap Tms S.

a. (EDAP) is the lower-risk stock at 0. 77β versus Profound Medical Corp. 's 1. 61β — meaning PROF is approximately 110% more volatile than EDAP relative to the S&P 500. On balance sheet safety, Profound Medical Corp. (PROF) carries a lower debt/equity ratio of 7% versus 143% for Edap Tms S. a. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Profound Medical Corp.

(PROF) is pulling ahead at 61. 1% versus 10. 3% for Edap Tms S. a. (EDAP). On earnings-per-share growth, the picture is similar: Profound Medical Corp. grew EPS 231. 8% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, PROF leads at 34. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Profound Medical Corp.

(PROF) is the more profitable company, earning 258. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 258. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EDAP leads at -35. 6% versus -256. 3% for PROF. At the gross margin level — before operating expenses — PROF leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Edap Tms S.

a. (EDAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Profound Medical Corp. (PROF) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EDAP: +18. 9%, PROF: -26. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PROF is a small-cap high-growth stock; EDAP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.